Kura Oncology Reports First Quarter 2024 Financial Results
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML –
– Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 –
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.